NCT03135769View on ClinicalTrials.gov

Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

December 2, 2020

Study Completion Date

March 17, 2021

Conditions
Gestational Trophoblastic Neoplasias (GTN)
Interventions
DRUG

Avelumab administration at 10mg/kg

Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).

Trial Locations (6)

13000

Institut Paoli-Calmettes, Marseille

14000

Centre Francois Baclesse, Caen

31000

Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse

33000

Institut Bergonie, Bordeaux

69495

Hospices Civils de Lyon - CHLS, Pierre-Bénite

75020

Aphp Hopital Tenon, Paris

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03135769 - Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias | Biotech Hunter | Biotech Hunter